Overall survival (OS) in contemporary randomized clinical trials (RCT) in advanced breast cancer (ABC)

被引：0
|
作者：
Katz, A. [1 ,2 ,3 ]
Saad, E. D. [1 ,2 ,3 ]
Buyse, M. E. [1 ,2 ,3 ]
机构：
[1] Sirio Libanes Hosp, Sao Paulo, Brazil
[2] Dendrix Res, Sao Paulo, Brazil
[3] Int Inst Drug Dev, Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1002
引用
收藏
页数：1
相关论文
共 50 条
  • [31] THE EFFECT OF CHEMOTHERAPY HOLIDAY ON THE OVERALL SURVIVAL OF PATIENTS WITH ADVANCED COLORECTAL CANCER: A META-ANALYSIS OF RANDOMIZED TRIALS
    Pereira, A. A. L.
    Rego, J. F. M.
    Hoff, P. M.
    Sasse, A.
    Riechelmann, R. P.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 181 - 181
  • [32] The validity of progression-free survival (PFS) 2 as a surrogate endpoint for overall survival (OS) in randomized controlled trials (RCTs) of advanced solid tumors.
    Woodford, Rachel
    Zhou, Deborah
    Kok, Peey-Sei
    Lord, Sally
    Marschner, Ian
    Friedlander, Michael
    Lee, Chee Khoon
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Nomograms for Predicting Local Recurrence, Distant Metastases, and Overall Survival for Patients With Locally Advanced Rectal Cancer on the Basis of European Randomized Clinical Trials
    Valentini, Vincenzo
    van Stiphout, Ruud G. P. M.
    Lammering, Guido
    Gambacorta, Maria Antonietta
    Barba, Maria Cristina
    Bebenek, Marek
    Bonnetain, Franck
    Bosset, Jean-Francois
    Bujko, Krzysztof
    Cionini, Luca
    Gerard, Jean-Pierre
    Roedel, Claus
    Sainato, Aldo
    Sauer, Rolf
    Minsky, Bruce D.
    Collette, Laurence
    Lambin, Philippe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (23) : 3163 - 3172
  • [34] Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced no(n)small-cell lung cancer?
    Pilz, Lothar R.
    Manegold, Christian
    Schmid-Bindert, Gerald
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2012, 1 (01) : 26 - 35
  • [35] Disease free survival as surrogate end-point for overall survival in adjuvant taxane-based chemotherapy for breast cancer: Analysis of randomized clinical trials
    Ciccarese, M.
    Bria, E.
    Cuppone, F.
    Nistico, C.
    Carlini, P.
    Natoli, G.
    Nuzzo, C.
    Terzoli, E.
    Cognetti, F.
    Giannarelli, D.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI15 - XI15
  • [36] Surrogate end points for overall survival in breast cancer trials: A review
    Fiteni, Frederic
    Bonnetain, Franck
    [J]. BREAST, 2016, 29 : 44 - 48
  • [37] Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials
    Joanne L. Blum
    Joseph Kohles
    Edward McKenna
    Nana Scotto
    Sylvia Hu
    Dawn Odom
    James A. Kaye
    Stefan Glück
    [J]. Breast Cancer Research and Treatment, 2011, 125 : 431 - 439
  • [38] Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials
    Blum, Joanne L.
    Kohles, Joseph
    McKenna, Edward
    Scotto, Nana
    Hu, Sylvia
    Odom, Dawn
    Kaye, James A.
    Glueck, Stefan
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 125 (02) : 431 - 439
  • [39] Highlighting the challenge of delayed overall survival (OS) curve separation in immunotherapy clinical trials.
    Steele, Savanna D.
    Wang, Song
    Solinger, Alan
    Combest, Austin J.
    Bonneterre, Marie-Edith Anne
    Reitsma, Dirk J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Overall Survival (OS) With Intensive Chemotherapy (IC) vs Non-IC in Patients With Newly Diagnosed (ND) AML from the Connect® Myeloid Disease Registry Ineligible for Randomized Clinical Trials (RCT)
    Erba, Harry P.
    Pollyea, Daniel A.
    Sekeres, Mikkael A.
    Garcia-Manero, Guillermo
    Seiter, Karen
    DeGutis, Irene S.
    Kiselev, Pavel
    McBride, Ali
    Yu, Edward
    Roboz, Gail J.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S229 - S230
12345